Imagion Biosystems raised millions in capital following FDA clearance of its Phase 2 clinical trial for MagSense, an agent ...

Innovation in the MRI market is centered around AI reconstruction, advanced magnet design, and workflow automation.

Human data demonstrates translation of key findings from preclinical studiesNovel F18 PET imaging agent designed to identify ...

Phase 2 is expected to be more complex than Phase 1, as cleanup crews deal with a part of the building that is structurally ...

FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial ...

FDA and Telix align on advancement into Part 2 of the ProstACT Global Phase 3 study in the United States.FDA agrees with the clinical protocol ...

Precision shapes modern life in ways often taken for granted. Navigation systems guide travel, medical scans reveal hidden ...

Shares in the AI-enabled heart imager have vaulted up to 50%, on the back of a $10-20 million investment from radiology giant ...

A depth-compensated diffractive optical element photoacoustic microscope enables more uniform photoacoustic imaging across tissue depths.

Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today ...

Modern OCT devices can look inside the eye without a scalpel - but they do not always capture everything that matters. Some ...